WINT RSI Chart
Last 7 days
9.5%
Last 30 days
-37.6%
Last 90 days
-30.7%
Trailing 12 Months
-83.5%
Historical Charts for Stock Metrics
Year | Q1 | Q2 | Q3 | Q4 |
---|---|---|---|---|
2019 | 1.4M | 993.0K | 595.5K | 198.0K |
2018 | 1.5M | 1.4M | 1.6M | 1.8M |
2017 | 2.2M | 2.0M | 1.7M | 1.5M |
2016 | 871.0K | 902.0K | 1.8M | 2.0M |
2015 | 2.4M | 1.9M | 1.4M | 987.0K |
2014 | 999.8K | 1.6M | 2.2M | 2.8M |
2013 | 267.0K | 449.0K | 509.0K | 388.0K |
2012 | 0 | 0 | 0 | 396.0K |
2011 | 0 | 0 | 0 | 582.0K |
Datesorted ascending | Name | Buy/Sell | $ Value | Avg. Price | # Shares | Title |
---|---|---|---|---|---|---|
Sep 27, 2023 | fraser craig | bought | 2,549 | 1.0199 | 2,500 | president and ceo |
Sep 26, 2023 | fraser craig | bought | 2,250 | 0.9 | 2,500 | president and ceo |
Aug 23, 2023 | simonson steven | acquired | - | - | 15,867 | svp, chief medical officer |
Aug 23, 2023 | curtis eric | acquired | - | - | 14,667 | svp & coo |
Aug 23, 2023 | williams leslie j. | acquired | - | - | 2,033 | - |
Aug 23, 2023 | strobeck mark | acquired | - | - | 2,300 | - |
Aug 23, 2023 | geffken daniel e. | acquired | - | - | 2,033 | - |
Aug 23, 2023 | fraser craig | acquired | - | - | 45,867 | president and ceo |
Aug 23, 2023 | scott robert a | acquired | - | - | 2,033 | - |
Apr 26, 2023 | fraser craig | bought | 2,649 | 1.77 | 1,497 | president and ceo |
Which funds bought or sold WINT recently?
View All DetailsDatesorted ascending | Fund Name | Type | % Chg | $ Change | $ Held | % Portfolio |
---|---|---|---|---|---|---|
May 15, 2024 | MORGAN STANLEY | sold off | -100 | -1.00 | - | -% |
May 15, 2024 | Alyeska Investment Group, L.P. | sold off | -100 | -98,156 | - | -% |
May 15, 2024 | DEERFIELD MANAGEMENT COMPANY, L.P. (SERIES C) | new | - | 215,328 | 215,328 | -% |
May 15, 2024 | CITADEL ADVISORS LLC | reduced | -72.05 | -23,642 | 3,772 | -% |
May 13, 2024 | FMR LLC | sold off | - | - | - | -% |
May 13, 2024 | UBS Group AG | reduced | -98.24 | -363 | 3.00 | -% |
May 13, 2024 | GEODE CAPITAL MANAGEMENT, LLC | reduced | -1.45 | -5,255 | 4,952 | -% |
May 10, 2024 | OSAIC HOLDINGS, INC. | unchanged | - | -1.00 | - | -% |
May 10, 2024 | WELLS FARGO & COMPANY/MN | added | 28.12 | -8.00 | 15.00 | -% |
May 10, 2024 | VANGUARD GROUP INC | unchanged | - | -15,198 | 14,741 | -% |
Unveiling Windtree Therapeutics, Inc.'s Major ShareHolders
Date Filed | Name of Filer | Percent of Class | No. of Shares | Form Type | |
---|---|---|---|---|---|
Peers (Alternatives to Windtree Therapeutics, Inc.)
Name | Mkt Capsorted ascending | Revenue | Price %, 1M | Returns, 1Y | P/E | P/S | Rev 1-Yr | Inc 1-Yr |
---|---|---|---|---|---|---|---|---|
LARGE-CAP | ||||||||
MRNA | 50.9B | 6.8B | -8.53 | 7.44 | ||||
HILS | 22.5B | 216.3K | -2.5K | 104.0K | ||||
ALNY | 18.9B | 2.0B | -56.9 | 9.43 | ||||
BMRN | 14.7B | 2.5B | 71.65 | 5.96 | ||||
INCY | 12.8B | 3.8B | 17.2 | 3.4 | ||||
MID-CAP | ||||||||
BBIO | 5.6B | 107.9M | -10.31 | 48.09 | ||||
APLS | 5.0B | 524.1M | -12.02 | 9.57 | ||||
AXSM | 3.6B | 251.0M | -12.28 | 14.5 | ||||
ARWR | 3.1B | 240.7M | -6.53 | 12.77 | ||||
ACAD | 2.4B | 813.8M | -1.4K | 3 | ||||
SMALL-CAP | ||||||||
CPRX | 1.9B | 411.3M | 29.91 | 4.73 | ||||
NVAX | 1.8B | 996.6M | -4.58 | 1.83 | ||||
CRBP | 480.9M | 881.7K | -14.25 | 481.06 | ||||
INO | 310.9M | 4.9M | -2.49 | 63.89 | ||||
IBIO | 17.1M | 2.1M | -0.74 | 7.61 |
Windtree Therapeutics, Inc. News
Income Statement (Quarterly) | ||||||||||||||||||||||
Description | (%) Q/Q | 2019Q4 | 2019Q3 | 2019Q2 | 2019Q1 | 2018Q4 | 2018Q3 | 2018Q2 | 2018Q1 | 2017Q4 | 2017Q3 | 2017Q2 | 2017Q2 | 2017Q1 | 2016Q4 | 2016Q3 | 2016Q2 | 2016Q1 | 2015Q4 | 2015Q3 | 2015Q2 | 2015Q1 |
Revenue | - | - | - | 0.00 | 0.00 | 0.00 | 0.00 | 1.00 | 0.00 | 0.00 | 0.00 | 1.00 | 1.00 | 0.00 | 1.00 | 1.00 | 0.00 | 0.00 | 1.00 | 0.00 | 0.00 | 1.00 |
Operating Expenses | -36.6% | 5.00 | 7.00 | 7.00 | 7.00 | 5.00 | 4.00 | 4.00 | - | - | - | - | - | - | - | - | - | - | - | - | - | - |
S&GA Expenses | -28.9% | 2.00 | 3.00 | 3.00 | 3.00 | 3.00 | 2.00 | 1.00 | - | - | - | - | - | - | - | - | - | - | - | - | - | - |
R&D Expenses | -43.6% | 2.00 | 4.00 | 3.00 | 3.00 | 2.00 | 2.00 | 3.00 | - | - | - | - | - | - | - | - | - | - | - | - | - | - |
Interest Expenses | 30.5% | 0.00 | 0.00 | 0.00 | 0.00 | 1.00 | 0.00 | 0.00 | - | - | - | - | - | - | - | - | - | - | - | - | - | - |
Net Income | -3.5% | -7.37 | -7.13 | -6.44 | -6.54 | -9.04 | -3.93 | -3.05 | - | - | - | - | - | - | - | - | - | - | - | - | - | - |
Balance Sheet | ||||||||||||||||||||||
Description | (%) Q/Q | 2024Q1 | 2023Q4 | 2023Q3 | 2023Q2 | 2023Q1 | 2022Q4 | 2022Q3 | 2022Q2 | 2022Q1 | 2021Q4 | 2021Q3 | 2021Q2 | 2021Q1 | 2020Q4 | 2020Q3 | 2020Q2 | 2020Q1 | 2019Q4 | 2019Q3 | 2019Q2 | 2019Q1 |
Assets | -7.1% | 30.00 | 32.00 | 36.00 | 41.00 | 35.00 | 38.00 | 48.00 | 52.00 | 67.00 | 75.00 | 85.00 | 91.00 | 136 | 113 | 119 | 128 | 113 | 119 | 101 | 105 | 112 |
Current Assets | -37.9% | 3.00 | 5.00 | 9.00 | 13.00 | 5.00 | 7.00 | 10.00 | 13.00 | 16.00 | 23.00 | 26.00 | 32.00 | 39.00 | 18.00 | 24.00 | 34.00 | 18.00 | 24.00 | 5.00 | 10.00 | 16.00 |
Cash Equivalents | -40.8% | 3.00 | 4.00 | 7.00 | 12.00 | 4.00 | 6.00 | 8.00 | 11.00 | 16.00 | 22.00 | 25.00 | 30.00 | 38.00 | 17.00 | 22.00 | 32.00 | 17.00 | 23.00 | 4.00 | 6.00 | 2.00 |
Net PPE | -11.5% | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 1.00 | 1.00 | 1.00 | 1.00 | 1.00 | 1.00 | 1.00 | 1.00 | 1.00 | 1.00 | 1.00 | 1.00 | 1.00 |
Goodwill | - | - | - | - | - | 3.00 | 3.00 | 4.00 | 4.00 | 16.00 | 16.00 | 16.00 | 16.00 | 16.00 | 16.00 | 16.00 | 16.00 | 16.00 | 16.00 | 16.00 | 16.00 | 16.00 |
Liabilities | -49.4% | 15.00 | 29.00 | 29.00 | 29.00 | 28.00 | 28.00 | 31.00 | 33.00 | 32.00 | 33.00 | 35.00 | 34.00 | 44.00 | 43.00 | 43.00 | 45.00 | 43.00 | 44.00 | 48.00 | 47.00 | 49.00 |
Current Liabilities | 25.0% | 5.00 | 4.00 | 4.00 | 4.00 | 3.00 | 2.00 | 4.00 | 5.00 | 5.00 | 5.00 | 5.00 | 5.00 | 7.00 | 6.00 | 6.00 | 12.00 | 7.00 | 8.00 | 16.00 | 16.00 | 17.00 |
Short Term Borrowings | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | 8.00 | 8.00 | 7.00 |
Shareholder's Equity | 354.8% | 15.00 | 3.00 | 7.00 | 12.00 | 7.00 | 10.00 | 17.00 | 19.00 | 35.00 | 42.00 | 50.00 | 57.00 | 91.00 | 70.00 | 76.00 | 83.00 | 70.00 | 75.00 | 53.00 | 58.00 | 63.00 |
Retained Earnings | 1.2% | -834 | -844 | -839 | -835 | -828 | -824 | -814 | -810 | -793 | -785 | -772 | -764 | -726 | -717 | -710 | -701 | -691 | -685 | -677 | -670 | -664 |
Additional Paid-In Capital | 0.2% | 853 | 851 | 850 | 850 | 839 | 838 | 835 | 833 | 831 | 830 | 825 | 824 | 821 | 790 | 789 | 788 | 765 | 763 | 734 | 732 | 730 |
Shares Outstanding | 53.1% | 9.00 | 6.00 | 5.00 | 5.00 | 1.00 | 1.00 | 1.00 | 1.00 | 1.00 | 1.00 | 0.00 | 0.00 | 0.00 | 0.00 | - | - | - | - | - | - | - |
Float | - | - | - | - | 6.00 | - | - | - | 9.00 | - | - | - | 44.00 | - | - | - | 67.00 | - | - | - | 31.00 | - |
Cashflow (Quarterly) | ||||||||||||||||||||||
Description | (%) Q/Q | 2024Q1 | 2023Q4 | 2023Q3 | 2023Q2 | 2023Q1 | 2022Q4 | 2022Q3 | 2022Q2 | 2022Q1 | 2021Q4 | 2021Q3 | 2021Q2 | 2021Q1 | 2020Q4 | 2020Q3 | 2020Q2 | 2020Q1 | 2019Q4 | 2019Q3 | 2019Q2 | 2019Q1 |
Cashflow From Operations | 17.4% | -2,947 | -3,567 | -3,854 | -3,497 | -2,519 | -3,380 | -4,099 | -5,258 | -6,715 | -4,932 | -5,281 | -7,403 | -6,048 | -4,539 | -8,256 | -7,038 | -5,482 | -5,459 | -3,824 | -6,621 | -8,759 |
Cashflow From Investing | - | - | - | -15.00 | - | - | - | - | 200 | -3.00 | -173 | -103 | -3.00 | - | -264 | -15.00 | - | - | -62.00 | 2,597 | 10,837 | 425 |
Cashflow From Financing | 98.5% | 1,034 | 521 | -233 | 10,716 | 591 | 1,116 | 1,157 | 895 | -89.00 | 2,912 | -40.00 | -1,119 | 27,608 | 48.00 | -1,137 | 21,246 | -199 | 22,739 | -346 | -27.00 | -598 |
Consolidated Statements of Operations (Unaudited) - USD ($) shares in Thousands, $ in Thousands | 3 Months Ended | |
---|---|---|
Mar. 31, 2024 | Mar. 31, 2023 | |
Research and development | $ 2,253 | $ 1,415 |
General and administrative | 2,152 | 2,292 |
Loss on impairment of goodwill | 0 | 484 |
Total operating expenses | 4,405 | 4,191 |
Operating loss | (4,405) | (4,191) |
Other income (expense): | ||
Gain on debt extinguishment | 14,520 | 0 |
Interest income | 30 | 44 |
Interest expense | (13) | (12) |
Other income, net | 201 | 48 |
Total other income, net | 14,738 | 80 |
Income (loss) before income taxes | 10,333 | (4,111) |
Income tax expense | (114) | 0 |
Net income (loss) | $ 10,219 | $ (4,111) |
Net income (loss) per common share | ||
Basic and diluted (in dollars per share) | $ 21.98 | $ (85.65) |
Weighted average number of common shares outstanding | ||
Basic and diluted (in shares) | 465 | 48 |
Condensed Consolidated Balance Sheets (Current Period Unaudited) - USD ($) $ in Thousands | Mar. 31, 2024 | Dec. 31, 2023 |
---|---|---|
Current Assets: | ||
Cash and cash equivalents | $ 2,547 | $ 4,319 |
Prepaid expenses and other current assets | 792 | 1,060 |
Total current assets | 3,339 | 5,379 |
Property and equipment, net | 162 | 183 |
Restricted cash | 9 | 150 |
Operating lease right-of-use assets | 1,343 | 1,444 |
Intangible assets | 25,250 | 25,250 |
Total assets | 30,103 | 32,406 |
Current Liabilities: | ||
Accounts payable | 1,689 | 809 |
Accrued expenses | 2,125 | 1,618 |
Operating lease liabilities - current portion | 446 | 436 |
Loans payable | 0 | 233 |
Other current liabilities | 725 | 900 |
Total current liabilities | 4,985 | 3,996 |
Operating lease liabilities - non-current portion | 1,038 | 1,161 |
Restructured debt liability - contingent milestone payments | 0 | 15,000 |
Other liabilities | 3,800 | 3,800 |
Deferred tax liabilities | 4,859 | 5,058 |
Total liabilities | 14,682 | 29,015 |
Stockholders’ Equity: | ||
Preferred stock, $0.001 par value; 5,000,000 shares authorized; 0 shares issued and outstanding at March 31, 2024 and December 31, 2023, respectively | 0 | 0 |
Common stock, $0.001 par value; 120,000,000 shares authorized; 510,181 and 333,145 shares issued at March 31, 2024 and December 31, 2023, respectively; 510,180 and 333,144 shares outstanding at March 31, 2024 and December 31, 2023, respectively | 1 | 0 |
Additional paid-in capital | 853,078 | 851,268 |
Accumulated deficit | (834,604) | (844,823) |
Treasury stock (at cost); 1 share | (3,054) | (3,054) |
Total stockholders’ equity | 15,421 | 3,391 |
Total liabilities & stockholders’ equity | $ 30,103 | $ 32,406 |